Notice of AGM

4 May 2011

LSE: VER

NOTICE OF ANNUAL GENERAL MEETING

Vernalis plc (LSE: VER) today gives notice of the following:

·; that copies of the Notice of Annual General Meeting ("AGM") and Form of Proxy have been sent to shareholders today. These documents are available on the Investor Centre page of the Company's web site at www.vernalis.com;

·; that its AGM will be held on Wednesday 15 June 2011. The meeting will be held at the offices of Morrison & Foerster (UK) LLP, CityPoint, One Ropemaker Street, London EC2Y 9AW, commencing at 11.00 am;

·; in accordance with Listing Rule 9.6.1, copies of these documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.hemscott.com/nsm.do;

·; the Group's Annual Report and Accounts was posted to shareholders on 21 April 2011 and is available for viewing on the Investor Centre page of the Company's web site at www.vernalis.com and the National Storage Mechanism at: www.hemscott.com/nsm.do.

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.